Skip to content
  • Home
  • Visit our other Journals
    • VJHemOnc
    • VJOncology
    • VJNeurology
    • VJDementia
    • VJHemOnc-E
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    ASH 2022
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

VJVirtual

GoCART Coalition: collaboration across stakeholders 2:50
GoCART Coalition: collaboration across stakeholders
Sofie Terwel • 28 Jan 2021
Collaboration in the field of cellular therapies 1:48
Collaboration in the field of cellular therapies
Sofie Terwel • 28 Jan 2021
Current activities of GoCART 1:41
Current activities of GoCART
Sofie Terwel • 28 Jan 2021
CART19-BE-01: ARI-0001 in CD19+ malignancies 8:17
CART19-BE-01: ARI-0001 in CD19+ malignancies
Valentín Ortiz-Maldonado • 11 Oct 2020
Immunotherapy for T-cell malignancies 7:38
Immunotherapy for T-cell malignancies
John DiPersio
Next questions in CAR-based therapies 3:56
Next questions in CAR-based therapies
John DiPersio
Adaptimmune: SPEAR T-cells 6:02
Adaptimmune: SPEAR T-cells
Helen Tayton-Martin • 15 Oct 2020
T-cells: challenges in bringing to market 4:21
T-cells: challenges in bringing to market
Helen Tayton-Martin • 15 Oct 2020
The cell therapy landscape: disruptive technologies 3:12
The cell therapy landscape: disruptive technologies
Helen Tayton-Martin • 15 Oct 2020
The potential of RegenMed in the oncology space 1:41
The potential of RegenMed in the oncology space
Helen Tayton-Martin • 15 Oct 2020
Progress in the face of COVID-19 1:37
Progress in the face of COVID-19
Janet Lambert • 5 Oct 2020
Meeting on the Mesa 2020 goes virtual 1:39
Meeting on the Mesa 2020 goes virtual
Janet Lambert • 5 Oct 2020
Key themes and discussions at Meeting on the Mesa 2020 1:49
Key themes and discussions at Meeting on the Mesa 2020
Janet Lambert • 5 Oct 2020
Introducing ARM: The Alliance for Regenerative Medicine 1:01
Introducing ARM: The Alliance for Regenerative Medicine
Janet Lambert • 5 Oct 2020
Challenges facing the regenmed sector in 2020 2:12
Challenges facing the regenmed sector in 2020
Janet Lambert • 5 Oct 2020
Putting the patient first in regenerative medicine 2:32
Putting the patient first in regenerative medicine
Paige Bischoff • 6 Oct 2020
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy